Role of KIR3DS1 in human diseases

Frontiers in Immunology

Volumn 3, Issue NOV, 2012, Pages

  Körner, Christian ^a   Altfeld, Marcus ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

HIV 1; HLA; Killer immunoglobulin like receptors; KIR3DS1; NK cell

Indexed keywords

EID: 84874211472     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00326     Document Type: Review

References (124)

1. Abi-Rached, L., and Parham, P. (2005). Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J. Exp. Med. 201,1319-1332.
2. Alter,G. ,Martin,M. P. ,Teigen,N. ,Carr, W. H. ,Suscovich,T. J. ,Schneidewind, A., et al. (2007). Differential natu-ral killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204, 3027-3036.
3. Alter, G., Rihn, S., Walter, K. , Nolting, A., Martin, M., Rosenberg, E. S., et al. (2009). HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells dur-ing acute human immunodeficiency virustype1infection. J. Virol. 83, 6798-6805.
4. Aranda-Romo, S., Garcia-Sepulveda, C. A., Comas-Garcia, A., Lovato-Salas, F., Salgado-Bustamante, M., Gomez-Gomez, A., et al. (2012). Killer-cell immunoglobulin-like receptors (KIR) in severe A (H1N1) 2009 influenza infections. Immunogenetics 64,653-662.
5. Arnheim, L., Dillner, J., and Sanjeevi, C. B. (2005). A population-based cohort study of KIR genes and geno-types in relation to cervical intraep-ithelial neoplasia. Tissue Antigens 65, 252-259.
6. Azuz-Lieberman, N., Markel, G., Mizrahi, S., Gazit, R., Hanna, J., Achdout, H., et al. (2005). The involvement of NK cells in ankylos-ing spondylitis. Int. Immunol. 17, 837-845.
7. Barbour, J. D., Sriram, U., Caillier, S. J., Levy, J. A., Hecht, F. M., and Oksenberg, J. R. (2007). Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog. 3,e43. doi: 10. 1371/journal. ppat. 0030043
8. Besson, C., Roetynck, S., Williams, F., Orsi, L., Amiel, C., Lepende-Ven, C., et al. (2007). Association of killer cell immunoglobulin-like receptor genes with Hodgkins lym-phoma in a familial study. PLoS ONE 2, e406. doi: 10. 1371/journal. pone. 0000406
9. Biassoni, R., Falco, M., Cambiaggi, A., Costa, P., Verdiani, S., Pende, D., et al. (1995). Amino acid substitu-tions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group1"NKclones. J. Exp. Med. 182, 605-609.
10. Bonagura, V. R., Du, Z., Ashouri, E., Luo, L., Hatam, L. J., Devoti, J. A., et al. (2010). Activating killer cell immunoglobulin-like receptors 3DS1and2DS1protectagainstdevel-oping the severe form of recurrent respiratory papillomatosis. Hum. Immunol. 71, 212-219.
11. Boulet, S., Sharafi, S., Simic, N., Bruneau, J., Routy, J. P., Tsoukas, C. M., et al. (2008). Increased pro-portion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 22,595-599.
12. Boyington, J. C., Motyka, S. A., Schuck, P., Brooks, A. G., and Sun, P. D. (2000). Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405,537-543.
13. Campbell, K. S., and Purdy, A. K. (2011). Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymor-phisms, evolution, crystal structures and mutations. Immunology 132, 315-325.
14. Carr, W. H., Pando, M. J., and Parham, P. (2005). KIR3DL1 polymorphisms thataffectNKcellinhibitionbyHLA-Bw4 ligand. J. Immunol. 175, 5222- 5229.
15. Carr, W. H., Rosen, D. B., Arase, H., Nixon, D. F., Michaelsson, J., and Lanier, L. L. (2007). Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodesaDAP12-associatedreceptor expressed on NK cells that triggers NK cell activation. J. Immunol. 178, 647-651.
16. Carrington, M., Wang, S., Martin, M. P., Gao, X., Schiffman, M., Cheng, J., et al. (2005). Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201,1069-1075.
17. Cella,M. ,Longo,A. ,Ferrara,G. B. ,Stro-minger,J. L. ,and Colonna,M. (1994). NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLAalleleswithisoleucine80. J. Exp. Med. 180,1235-1242.
18. Chan, H. W., Kurago, Z. B., Stewart, C. A., Wilson, M. J., Martin, M. P., Mace, B. E., et al. (2003). DNA methylation maintains allele-specific KIR gene expression in human nat-ural killer cells. J. Exp. Med. 197, 245-255.
19. Chan, H. W., Miller, J. S., Moore, M. B., and Lutz, C. T. (2005). Epigenetic control of highly homol-ogous killer Ig-like receptor gene alleles. J. Immunol. 175, 5966- 5974.
20. Crum, K. A., Logue, S. E., Curran, M. D., and Middleton, D. (2000). Devel-opment of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires. Tissue Antigens 56,313-326.
21. Davies,G. E. ,Locke,S. M. ,Wright,P. W., Li,H. ,Hanson,R. J. ,Miller,J. S. ,et al. (2007). Identificationofbidirectional promoters in the human KIR genes. Genes Immun. 8, 245-253.
22. Diaz-Pena, R., Blanco-Gelaz, M. A., and Lopez-Larrea, C. (2009). KIR genes and their role in spondy-loarthropathies. Adv. Exp. Med. Biol. 649,286-299.
23. Diaz-Pena, R., Blanco-Gelaz, M. A., Suarez-Alvarez, B., Martinez-Borra, J., Lopez-Vazquez, A., Alonso-Arias, R, et al. (2008). Activating KIR genes are associated with ankylosing spondylitis in Asian populations. Hum. Immunol. 69,437-442.
24. Diaz-Pena, R., Vidal-Castineira, J. R., Alonso-Arias, R., Suarez-Alvarez, B., Vicario, J. L., Solana, R. et al. (2010). Association of the KIR3DS1z.ast;013 and KIR3DL1z.ast;004 alleles with sus-ceptibility to ankylosing spondyli-tis. Arthritis Rheum. 62, 1000- 1006.
25. Dohring,C. ,Samaridis,J. ,and Colonna, M. (1996). Alternatively spliced forms of human killer inhibitory receptors. Immunogenetics 44, 227-230.
26. Dougados, M., and Baeten, D. (2011). Spondyloarthritis. Lancet 377, 2127- 2137.
27. Fadda, L., Borhis, G., Ahmed, P., Cheent, K., Pageon, S. V., Cazaly, A, et al. (2010). Peptide antagonism as a mechanism for NK cell activation. Proc. Natl. Acad. Sci. U. S. A. 107, 10160-10165.
28. Fadda, L., O'Connor, G. M., Kumar, S., Piechocka-Trocha, A, Gardiner, C. M., Carrington, M., et al. (2011). Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J. Virol. 85,5970-5974.
29. Fan, Q. R., Long, E. O., and Wiley, D. C. (2001). Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 com-plex. Nat. Immunol. 2, 452-460.
30. Faure, M., and Long, E. O. (2002). KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J. Immunol. 168, 6208- 6214.
31. Foley, B. A., De Santis, D., Van Beelen, E., Lathbury, L. J., Christiansen, F. T., and Witt, C. S. (2008). The reactivity of Bw4+ HLA-B and HLA-A alle-les with KIR3DL1: implications for patient and donor suitability for haploidentical stemcelltrans plantations. Blood 112, 435-443.
32. Gabriel, I. H., Sergeant, R., Szydlo, R., Apperley, J. F., Delavallade, H., Alsuliman, A, et al. (2010). Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with mul-tiple myeloma. Blood 116, 2033- 2039.
33. Gagne, K., Busson, M., Bignon, J. D., Balere-Appert, M. L., Loiseau, P., Dormoy, A, et al. (2009). Donor KIR3DL1/3DS1 gene and recipi-ent Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplanta-tion. Biol. Blood Marrow Transplant. 15, 1366-1375.
34. Gardiner, C. M., Guethlein, L. A., Shilling, H. G., Pando, M., Carr, W. H., Rajalingam, R, et al. (2001). Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166,2992-3001.
35. Gaudieri,S. ,Desantis,D. ,Mckinnon,E., Moore,C. ,Nolan,D. ,Witt,C. S. ,et al. (2005). Killer immunoglobulin-like receptors and HLA act both inde-pendentlyandsynergisticallytomod-ify HIV disease progression. Genes Immun. 6, 683-690.
36. Gendzekhadze, K., Norman, P. J., Abi-Rached, L., Graef, T., Moesta, A. K., Layrisse, Z, et al. (2009). Co-evolution of KIR2DL3 with HLA-Cin a human population retaining min-imal essential diversity of KIR and HLA class I ligands. Proc. Natl. Acad. Sci. U. S. A. 106, 18692-18697.
37. Gendzekhadze, K., Norman, P. J., Abi-Rached, L., Layrisse, Z., and Parham, P. (2006). High KIR diversity in Amerindians is maintained using few gene-content haplotypes. Immuno-genetics 58, 474-480.
38. Gillespie, G. M., Bashirova, A., Dong, T., Mcvicar, D. W., Rowland-Jones, S. L., and Carrington, M. (2007). Lack of KIR3DS1 binding to MHC class IBw4tetramersincomplexwith CD8+ T cell epitopes. AIDS Res. Hum. Retroviruses 23,451-455.
39. Gourraud,P. A. ,Meenagh,A. ,Cambon-Thomsen, A., and Middleton, D. (2010). Linkage disequilibrium orga-nization of the human KIR super-locus:implicationsforKIRdataanal-yses. Immunogenetics 62,729-740.
40. Guethlein, L. A., Abi-Rached, L, Ham-mond, J. A., and Parham, P. (2007). The expanded cattle KIR genes are orthologous to the conserved single-copy KIR3DX1 gene of primates. Immunogenetics 59,517-522.
41. Gumperz,J. E. ,Litwin,V. ,Phillips,J. H., Lanier, L. L., and Parham, P. (1995). The Bw4 public epitope of HLA-B molecules confersreactivitywithnat-ural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181,1133-1144.
42. Hansasuta,P. ,Dong,T. ,Thananchai,H., Weekes, M., Willberg, C., Aldemir, H. ,et al. (2004). RecognitionofHLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34, 1673-1679.
43. Harvey, D., Pointon, J. J., Sleator, C., Meenagh, A., Farrar, C., Sun, J. Y, et al. (2009). Analysis of killer immunoglobulin-like receptor genes in ankylosing spondylitis. Ann. Rheum. Dis. 68,595-598.
44. Hiby, S. E., Apps, R., Sharkey, A. M., Farrell, L. E., Gardner, L, Mulder, A., et al. (2010). Maternal activating KIRs protect against human reproductivefailuremediatedbyfetal HLA-C2. J. Clin. Invest. 120, 4102- 4110.
45. Hiby, S. E., Regan, L., Lo, W, Farrell, L., Carrington, M., and Mof-fett, A. (2008). Association of mater-nal killer-cell immunoglobulin-like receptors and parental HLA-C geno-types with recurrent miscarriage. Hum. Reprod. 23, 972-976.
46. Hiby, S. E., Walker, J. J., OShaughnessy K, M., Redman, C. W., Carrington, M., Trowsdale, J, et al. (2004). Com-binations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive suc-cess. J. Exp. Med. 200,957-965.
47. Hickman, H. D., Luis,A. D., Bardet,W., Buchli, R., Battson, C. L., Shearer, M. H, et al. (2003). Cutting edge: class I presentation of host peptides follow-ing HIV infection. J. Immunol. 171, 22-26.
48. Hollenbach, J. A., Meenagh, A., Sleator, C., Alaez, C., Bengoche, M., Canossi, A, et al. (2010). Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the15thInternationalHistocompati-bilityWorkshop:worldwidevariation in the KIR loci and further evidence fortheco-evolutionof KIRandHLA. Tissue Antigens 76, 9-17.
49. Hsu, K. C., Chida, S., Geraghty, D. E., andDupont,B. (2002). Thekillercell immunoglobulin-like receptor (KIR) genomic region: gene-order, hap-lotypes and allelic polymorphism. Immunol. Rev. 190, 40-52.
50. Jamil, K. M., and Khakoo, S. I. (2011). KIR/HLA interactions and pathogen immunity. J. Biomed. Biotechnol. 2011,298348
51. Jamil, K. M., and Khakoo, S. I. (2011). KIR/HLA interactions and pathogen immunity. J. Biomed. Biotechnol. 2011,298348. Jiao, Y. L., Zhang, B. C., You, L., Li, J. F., Zhang, J., Ma, C. Y., et al. (2010). Polymorphisms of KIR gene and HLA-C alleles: possible asso-ciation with susceptibility to HLA-B27-positivepatientswithankylosing spondylitis. J. Clin. Immunol. 30, 840-844.
52. Karabon, L., Jedynak, A., Giebel, S., Wolowiec, D., Kielbinski, M., Woszczyk, D, et al. (2011). KIR/HLA gene combinations influence sus-ceptibility to B-cell chronic lym-phocytic leukemia and the clinical course of disease. Tissue Antigens 78, 129-138.
53. Khakoo, S. I., Geller, R., Shin, S, Jenk-ins, J. A., and Parham, P. (2002). The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J. Exp. Med. 196,911-921.
54. Kim,S. ,Sunwoo,J. B. ,Yang,L. ,Choi,T., Song,Y. J. ,French,A. R. ,et al. (2008). HLA alleles determine differences in human natural killer cell responsive-ness and potency. Proc. Natl. Acad. Sci. U. S. A. 105,3053-3058.
55. Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., and Phillips, J. H. (1998). Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391,703-707.
56. Li, H., Pascal, V., Martin, M. P., Carrington, M., and Anderson, S. K. (2008). Genetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet. 4, e1000254. doi: 10. 1371/journal. pgen. 1000254
57. Li, H., Peng, S. L., Cui, Y., Fu, Q. X., Zhou, Y., Wang, Q. L, et al. (2010). Kinetics of interaction of HLA-B2705 with natural killer cell immunoglobulin-likereceptor3DS1. Protein Pept. Lett. 17,547-554.
58. Litwin, V., Gumperz, J., Parham, P., Phillips,J. H. ,andLanier,L. L. (1994). NKB1: a natural killer cell receptor involved in the recognition of poly-morphic HLA-B molecules. J. Exp. Med. 180,537-543.
59. Long, B. R., Ndhlovu, L. C, Oksenberg, J. R., Lanier, L. L., Hecht, F. M., Nixon, D. F., et al. (2008). Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J. Virol. 82,4785-4792.
60. Lopez-Larrea, C., Blanco-Gelaz, M. A., Torre-Alonso, J. C., Bruges Armas, J., Suarez-Alvarez, B., Pruneda, L, et al. (2006). Contribu-tion of KIR3DL1/3DS1 to ankylos-ing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res. Ther. 8,R101.
61. Lopez-Vazquez, A., Rodrigo, L., Martinez-Borra, J., Perez, R., Rodriguez, M., Fdez-Morera, J. L, et al. (2005). Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor3DS1geneagainstthedevel-opment of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis. 192,162-165
62. Maenaka, K., Juji, T., Nakayama, T., Wyer, J. R., Gao, G. F., Maenaka, T, et al. (1999). Killer cell immunoglob-ulin receptors and T cell receptors bind peptide-major histocompatibil-ity complex class I with distinct ther-modynamic and kinetic properties. J. Biol. Chem. 274,28329-28334.
63. Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W. E., Ciccone, E., Moretta, A, et al. (1995). Peptide specificityintherecognitionof MHC class I by natural killer cell clones. Science 267,1016-1018.
64. Mandelboim, O., Wilson, S. B., Vales-Gomez, M., Reyburn, H. T., and Strominger,J. L. (1997). Selfandviral peptides can initiate lysis by autolo-gous natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 94,4604-4609.
65. Marcenaro, E., Carlomagno, S., Pesce, S., Della Chiesa, M., Moretta, A., and Sivori, S. (2011). Role of alloreac-tive KIR2DS1(+) NK cells in hap-loidentical hematopoietic stem cell transplantation. J. Leukoc. Biol. 90, 661-667.
66. Marsh, S. G., Parham, P., Dupont, B., Geraghty, D. E., Trowsdale, J, Mid-dleton, D., et al. (2003). Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens 62, 79-86.
67. Martin, M. P., Bashirova, A., Traherne, J., Trowsdale, J., and Carrington, M. (2003). Cutting edge: expansion of the KIR locus by unequal crossing over. J. Immunol. 171,2192-2195.
68. Martin, M. P., Gao, X., Lee, J. H, Nel-son, G. W., Detels, R., Goedert, J. J., et al. (2002). Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31,429-434.
69. Martin, M. P., Pascal, V., Yeager, M., Phair, J., Kirk, G. D., Hoots, K, et al. (2007a). AmutationinKIR3DS1that results in truncation and lack of cell surface expression. Immunogenetics 59,823-829.
70. Martin, M. P., Qi, Y., Gao, X., Yamada, E., Martin, J. N., Pereyra, F, et al. (2007b). Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39,733-740.
71. Meiring, H. D., Soethout, E. C., Poelen, M. C. ,Mooibroek,D. ,Hoogerbrugge, R., Timmermans, H, et al. (2006). Stable isotope tagging of epitopes: a highly selective strategy for the iden-tificationof majorhistocompatibility complex class I-associated peptides induced upon viral infection. Mol. Cell. Proteomics 5,902-913.
72. Moesta, A. K., Norman, P. J., Yawata, M., Yawata, N., Gleimer, M., and Parham, P. (2008). Synergistic poly-morphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 180,3969-3979.
73. Moretta, A., Vitale, M., Bottino, C., Orengo, A. M., Morelli, L., Augugliaro, R, et al. (1993). P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604.
74. Morvan, M., David, G., Sebille, V., Perrin, A., Gagne, K., Willem, C, et al. (2008). Autologous and allo-geneicHLAKIRligandenvironments and activating KIR control KIR NK-cell functions. Eur. J. Immunol. 38, 3474-3486.
75. Morvan, M., Willem, C., Gagne, K., Kerdudou, N., David, G., Sebille, V, et al. (2009). Phenotypic and func-tional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demon-strate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J. Immunol. 182,6727-6735.
76. Mousavi, T., Poormoghim, H., Moradi, M., Tajik, N., Shahsavar, F., and Asadifar, B. (2010). Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against ankylos-ing spondylitis. Iran J. Immunol. 7, 88-95.
77. Norman, P. J., Abi-Rached, L., Gendzekhadze, K., Korbel, D., Gleimer, M., Rowley, D, et al. (2007). Unusual selection on the KIR3DL1/S1 natural killer cell recep-tor in Africans. Nat. Genet. 39, 1092-1099.
78. O'Connell, K. A., Han, Y., Williams, T. M., Siliciano, R. F., and Blankson, J. N. (2009). Role of natural killercellsinacohortofelitesuppres-sors: low frequency of the protective KIR3DS1 allele and limited inhibi-tion of human immunodeficiency virus type 1 replication in vitro. J. Virol. 83,5028-5034.
79. O'Connor, G. M., Guinan, K. J, Cunningham, R. T., Middleton, D., Parham, P., and Gardiner, C. M. (2007). Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178, 235-241.
80. O'Connor, G. M, Seich Al Basatena, N. K., Olavarria, V., Macnamara, A., Vine, A., Ying, Q., et al. (2012). In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retro-viral infection. Hum. Immunol. 73, 783-737.
81. O'Connor, G. M., Yamada, E, Rampersaud, A., Thomas, R., Carrington, M., and Mcvicar, D. W. (2011). Analysis of binding of KIR3DS1z.ast;;014 to HLA suggests distinct evolutionary history of KIR3DS1. J. Immunol. 187, 2162-2171.
82. Pando, M. J., Gardiner, C. M., Gleimer, M., Mcqueen, K. L., and Parham, P. (2003). The protein made from a common allele of KIR3DL1 (3DL1z.ast;004)ispoorlyexpressedatcell surfaces due to substitution at posi-tions86inIgdomain0and182 in Ig domain 1. J. Immunol. 171, 6640-6649.
83. Parham, P., Norman, P. J., Abi-Rached, L., and Guethlein, L. A. (2011). Vari-able NK cell receptors exemplified by human KIR3DL1/S1. J. Immunol. 187, 11-19.
84. Pascal, V., Yamada, E., Martin, M. P., Alter, G., Altfeld, M., Metcalf, J. A, et al. (2007). Detection of KIR3DS1 onthecellsurfaceofperipheralblood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection. J. Immunol. 179, 1625- 1633.
85. Pelak, K., Need, A. C., Fellay, J, Shianna, K. V., Feng, S., Urban, T. J., Ge, D., et al. (2011). Copy number vari-ation of KIR genes influences HIV-1 control. PLoS Biol. 9, e1001208. doi: 10. 1371/journal. pbio. 1001208
86. Peruzzi, M., Wagtmann, N., and Long, E. O. (1996). A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discrimi-natesamongpeptidesboundtoHLA-Bz.ast;2705. J. Exp. Med. 184,1585-1590
87. Purdy, A. K., and Campbell, K. S. (2009). Natural killer cells and can-cer:regulationbythekillercellIg-like receptors (KIR). Cancer Biol. Ther. 8, 2211-2220.
88. Qi, Y., Martin, M. P., Gao, X., Jacobson, L., Goedert, J. J, Buch-binder, S., et al. (2006). KIR/HLA pleiotropism: protection against both HIV and opportunistic infec-tions. PLoS Pathog. 2, e79. doi: 10. 1371/journal. ppat. 0020079
89. Rajagopalan, S., and Long, E. O. (1997). The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits pep-tide selectivity. J. Exp. Med. 185, 1523-1528.
90. Rajagopalan,S. ,and Long,E. O. (1999). A human histocompatibility leuko-cyteantigen(HLA)-G-specificrecep-torexpressedonallnaturalkillercells. J. Exp. Med. 189,1093-1100.
91. Robinson, J., Mistry, K., Mcwilliam, H., Lopez, R., and Marsh, S. G. (2010). IPD - the immuno polymor-phismdatabase. NucleicAcidsRes. 38, D863- D869.
92. Sambrook, J. G., Bashirova, A, Ander-sen, H., Piatak, M., Vernikos, G. S., Coggill, P., et al. (2006). Identification of the ancestral killer immunoglobulin-like receptor gene in primates. BMC Genomics 7, 209. doi: 10. 1186/1471-2164-7-209
93. Santourlidis, S., Graffmann, N., Christ, J., and Uhrberg, M. (2008). Lineage-specific transition of histone signa-tures in the killer cell Ig-like receptor locus from hematopoietic progeni-tortoNKcells. J. Immunol. 180, 418-425.
94. Santourlidis,S. ,Trompeter, H. I. ,Wein-hold, S., Eisermann, B., Meyer, K. L., Wernet, P., et al. (2002). Crucial role of DNA methylation in determi-nation of clonally distributed killer cell Ig-like receptor expression pat-ternsinNKcells. J. Immunol. 169, 4253-4261.
95. Sharma, D., Bastard, K., Guethlein, L. A., Norman, P. J., Yawata, N., Yawata, M, et al. (2009). Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combinetoformreceptorswithhigh, moderate,andnoavidityforthecom-plex of a peptide derived from HIV and HLA-Az.ast;2402. J. Immunol. 183, 4569-4582.
96. Stern, M., Ruggeri, L., Capanni, M., Mancusi, A., and Velardi, A. (2008). Human leukocyte antigens A23,A24, and A32 but not A25 are ligands for KIR3DL1. Blood 112,708-710.
97. Stewart, C. A., Laugier-Anfossi, F., Vely, F., Saulquin, X., Riedmuller, J, Tisserant, A., et al. (2005). Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. U. S. A. 102,13224-13229.
98. Stewart,C. A. ,van Bergen,J. ,andTrows-dale, J. (2003). Different and diver-gent regulation of the KIR2DL4 and KIR3DL1 promoters. J. Immunol. 170,6073-6081.
99. Stulberg, M. J., Wright, P. W., Dang, H, Hanson,R. J. ,Miller,J. S. ,andAnder-son, S. K. (2007). Identification of distalKIRpromotersandtranscripts. Genes Immun. 8, 124-130.
100. Tajik, N., Shahsavar, F, Poor-moghim, H., Radjabzadeh, M. F., Mousavi, T., and Jalali, A. (2011). KIR3DL1+HLA-B Bw4Ile80 and KIR2DS1+HLA-C2 combina-tions are both associated with anky-losing spondylitis in the Iranian pop-ulation. Int. J. Immunogenet. 38, 403-409.
101. Thananchai, H., Gillespie, G., Martin, M. P., Bashirova, A., Yawata, N., Yawata, M, et al. (2007). Cutting Edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178,33-37.
102. Thomas,G. P. ,andBrown,M. A. (2010). Genetics and genomics of ankylos-ing spondylitis. Immunol. Rev. 233, 162-180.
103. Thomas, R., Yamada, E., Alter, G, Mar-tin, M. P., Bashirova, A. A., Norman, P. J., et al. (2008). Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J. Immunol. 180,6743-6750.
104. Tomescu, C., Abdulhaqq, S., and Mon-taner, L. J. (2011). Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin. Exp. Immunol. 164, 158-169.
105. Tomescu, C., Duh, F. M., Lanier, M. A., Kapalko, A., Mounzer, K. C., Martin, M. P. ,et al. (2010). Increasedplasma-cytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. AIDS 24, 2151-2160.
106. Traherne, J. A., Martin, M., Ward, R., Ohashi, M., Pellett, F, Glad-man, D., et al. (2010). Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum. Mol. Genet. 19, 737-751.
107. Trowsdale, J. (2001). Genetic and func-tional relationships between MHC andNKreceptorgenes. Immunity 15, 363-374.
108. Trundley, A., Frebel, H., Jones, D., Chang, C., and Trowsdale, J. (2007). Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 andDX9antibodies. Eur. J. Immunol. 37, 780-787.
109. Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert-Weidenbach, K., Corliss, B, et al. (1997). Human diversity in killer cell inhibitory receptor genes. Immunity 7,753-763.
110. Vales-Gomez, M., Reyburn, H. T., Erskine, R. A., and Strominger, J. (1998). Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell recep-tors. Proc. Natl. Acad. Sci. U. S. A. 95, 14326-14331.
111. Valiante, N. M., Uhrberg, M., Shilling, H. G., Lienert-Weidenbach, K., Arnett, K. L., D'Andrea, A, et al. (1997). Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7, 739-751.
112. van Bergen, J., Stewart, C. A, Van Den Elsen, P. J., and Trowsdale, J. (2005). Structuralandfunctionaldif-ferences between the promoters of independentlyexpressedkillercellIg-like receptors. Eur. J. Immunol. 35, 2191-2199.
113. Venstrom, J. M., Gooley, T. A, Spell-man, S., Pring, J., Malkki, M., Dupont,B. ,et al. (2010). Donor acti-vating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 115, 3162- 3165.
114. Verheyden, S., Schots, R., Duquet, W., and Demanet, C. (2005). A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19, 1446- 1451.
115. Vivian, J. P., Duncan, R. C., Berry, R., O'Connor, G. M., Reid, H. H., Beddoe, T, et al. (2011). Killer cell immunoglobulin-like receptor 3DL1-mediated recog-nitionof humanleukocyteantigenB. Nature 479,401-405.
116. Vivier, E., Nunes, J. A., and Vely, F. (2004). Natural killer cell signal-ing pathways. Science 306, 1517- 1519.
117. Wang, S., Li, G., Ge, R., Duan, Z., Zeng, Z., Zhang, T, et al. (2012). Associ-ation of KIR genotype with suscep-tibility to HLA-B27-positive ankylosing spondylitis. Mod. Rheumatol. doi: 10. 1007/s10165-012-0692-z [Epub ahead of print].
118. Williams, F., Maxwell, L. D, Half-penny, I. A., Meenagh,A., Sleator, C., Curran, M. D., et al. (2003). Multi-ple copies of KIR 3DL/S1 and KIR 2DL4 genes identified in a number of individuals. Hum. Immunol. 64, 729-732.
119. Wilson, M. J., Torkar, M., Haude, A., Milne, S., Jones, T., Sheer, D, et al. (2000). Plasticity in the organization and sequences of human KIR/ILT gene families. Proc. Natl. Acad. Sci. U. S. A. 97, 4778-4783.
120. Winter, C. C., and Long, E. O. (1997). A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to dis-criminate between the two groups of HLA-C allotypes. J. Immunol. 158, 4026-4028.
121. Wu, J., and Lanier, L. L. (2003). Natural killer cell sandcancer. Adv. Cancer Res. 90, 127-156.
122. Yawata, M., Yawata, N., Draghi, M., Little, A. M., Partheniou, F, and Parham,P. (2006). RolesforHLAand KIR polymorphisms in natural killer cell repertoire selection and modula-tion of effector function. J. Exp. Med. 203, 633-645.
123. Zappacosta, F., Borrego, F., Brooks, A. G., Parker, K. C., and Coligan, J. E. (1997). Peptides isolated from HLA-Cwz.ast;;0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc. Natl. Acad. Sci. U. S. A. 94, 6313-6318.
124. Zhi-Ming,L.,Yu-Lian,J.,Zhao- Lei,F.,Chun-Xiao,W.,Zhen- Fang,D.,Bing- hang,Z.,etal. (2007). Polymorphismsofkillercell immunoglobulin-likereceptorgene: possible associationwithsuscepti- bilitytoorclearanceofhepatitis B virusinfectioninChineseHan